[Postoperative adjuvant treatment for non-small cell lung cancer].
The subjects in this study were patients who received postoperative adjuvant treatment for non-small cell lung cancer, had pathological stages I through IIIA, and underwent complete resection of their tumors. Many phase III trials with chemotherapy, radiotherapy, chemoradiotherapy or other modalities as postoperative adjuvant treatment have been conducted. However, no adjuvant treatment has been established as a result of those trials.
Ichinose
Yukito
Y
Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka 811-1395, Japan.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D017326:Clinical Trials, Phase III as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D011182:Postoperative Care; D015996:Survival Rate
D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin